ArticlePloS one2025
Alzheimer's disease classification using a hybrid deep learning approach with multi-layer U-net segmentation and XAI driven analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunopharmacological design of a multi-epitope vaccine targeting hepatitis C virus genotype 3a.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Next generation preventive neurology: how artificial intelligence and machine learning are reshaping Alzheimer's disease research.Behavioral and brain functions : BBF · 2026Review
- PredatorNet: a clinically trustworthy deep learning framework for multi-class Alzheimer's disease classification using MRI.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative illness causing a significant decrease in cognitive function, and early, accurate diagnosis is of great therapeutic and diagnostic value. Currently, there is promising potential for applying various types of artificial intelligence techniques, such as enhanced models of deep learning, for classifying Alzheimer's disease. Therefore, this study proposes an Outline of deep learning to classify Alzheimer's disease with segmentation using the Multi-Layer U-Net and a hybrid classification approach combining multi-scale EfficientNet with SVM. The proposed methodology consists of a four-phase process: (1) Whole brain segmentation, (2) Gray matter segmentation using multi-layer U-Net segmentation, (3) Feature extraction using Multi-Scale Efficient Net with SVM for classification, and (4) XAI (explainable AI) techniques by integrating Saliency Map Quantitative Analysis for increased clinical trustworthiness and model interpretability. It is found that the experiment results provide promising classification performance for three classes - Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI) and Cognitively Normal (CN) with an overall accuracy of 97.78% ± 0.54%, precision of 97.18% ± 1.14% (AD), 97.78% ± 0.29% (CN) and 97.03% ± 1.10% (MCI), recall of 97.90% ± 0.77% (AD), 97.49% ± 1.34% (CN) and 97.25% ± 0.99% (MCI), and F1 score of 97.74% ± 0.63% (AD), 97.78% ± 0.79% (CN), and 97.54% ± 0.69%(MCI). The results obtained underscore the elegance of the proposed approach in correctly classifying Alzheimer's disease stages. Future work will evaluate the model on publicly accessible Alzheimer's disease MRI datasets and incorporate advanced XAI techniques for increased interpretability and diagnostic reliability. The work focuses on Human Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.